Check for updates

OPEN ACCESS

EDITED BY Ahmed Esmat Abdel Moneim, Helwan University, Egypt

REVIEWED BY

Jonathan Soldera, University of Caxias do Sul, Brazil Alicia Calleja Fernández, Open University of Catalonia, Spain

*CORRESPONDENCE Song Tang, I tangsong0802@163.com Ying Lin, I linwy@mail.sysu.edu.cn Wa Zhong, I zhongwa@mail.sysu.edu.cn

 $^{\mathrm{t}}\mathrm{These}$ authors have contributed equally to this work

RECEIVED 16 December 2024 ACCEPTED 08 April 2025 PUBLISHED 22 April 2025

CITATION

Wu Z, Ni C, Ye Z, Xia Z, Li L, Yu Z, Tang S, Lin Y and Zhong W (2025) The efficacy of aminosalicylates in acute radiation enteritis: a systematic review and meta-analysis. *Front. Pharmacol.* 16:1544981. doi: 10.3389/fphar.2025.1544981

COPYRIGHT

© 2025 Wu, Ni, Ye, Xia, Li, Yu, Tang, Lin and Zhong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

The efficacy of aminosalicylates in acute radiation enteritis: a systematic review and meta-analysis

Zhendong Wu^{1,2†}, Chuyan Ni^{3†}, Zhen Ye^{1,4}, Zhongsheng Xia¹, Li Li⁵, Zhong Yu¹, Song Tang⁶*, Ying Lin^{1,4}* and Wa Zhong¹*

¹Department of Gastroenterology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China, ²Department of Gastroenterology, Dongguan Songshan Lake Tungwah Hospital, Dongguan, Guangdong, China, ³Department of Gastroenterology, Longgang District People's Hospital of Shenzhen, Shenzhen, Guangdong, China, ⁴Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China, ⁵Department of Emergency, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China, ⁶Department of Gastrointestinal Surgery, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, Guangdong, China

Background and purpose: Aminosalicylates have been used for the prevention and treatment of radiation enteritis (RE) for more than 50 years. However, their effectiveness in acute radiation enteritis (ARE) has been controversial. We conducted a meta-analysis to clarify the clinical efficacy of aminosalicylates in controlling the symptoms of ARE.

Materials and methods: We searched PubMed, Cochrane Library, Embase, and Web of Science for studies published before January 2020. Eligible randomized controlled trials (RCTs) comparing the incidence of diarrhea, abdominal pain, constipation, tenesmus, and hematochezia between the aminosalicylates and control groups were included. Subgroup analyses were conducted based on different drugs and doses. Publication bias was assessed using funnel plots.

Results: Seven RCTs with 613 patients were included. Aminosalicylates reduced the incidence of mild to moderate diarrhea (P < 0.05), while total diarrhea, severe diarrhea, abdominal pain, hematochezia, tenesmus, and constipation showed no significant differences from the control group. Subgroup analysis showed that sulfasalazine (SASP) reduced mild to moderate diarrhea (P < 0.05), whereas 5-aminosalicylic acid (5-ASA) increased total and severe diarrhea (P < 0.05). Additionally, when aminosalicylate doses exceeded 2 g/d, diarrhea incidence increased (P < 0.05).

Conclusion: SASP is a safe and effective treatment for mild to moderate diarrhea, while 5-ASA may increase diarrhea incidence in ARE patients. Aminosalicylates at ≤ 2 g/d are safe for ARE, but higher doses may worsen diarrhea.

KEYWORDS

aminosalicylates, SASP, 5-ASA, radiation enteritis, meta-analysis

Introduction

Globocan 2020 data indicates that pelvic malignancies account for 28.4% of all cancer cases globally (Sung et al., 2021). Radiation therapy is an essential treatment for pelvic malignancies, but approximately 90% of patients undergo permanent changes in bowel habits following pelvic radiation therapy (Andreyev, 2007). Acute radiation enteritis (ARE) refers to gastrointestinal toxicity occurring within 3 months after radiation therapy, involving the small intestine, colon, and rectum, and characterized by symptoms such as diarrhea, abdominal pain, constipation, tenesmus and rectal bleeding (Loge et al., 2020; P et al., 2024; Zimmerer et al., 2008). With the increase of tumor incidence, the prevalence of RE is also on the rise. It affects not only the continuity of anti-tumor therapy, but also reduces the quality of life for the patients. Even a single day of unplanned interruption during radiation therapy can potentially reduce local control rates by 1%-1.4% (P et al., 2024). However, there are no gold standard for the prevention and treatment of acute radiation enteritis.

Aminosalicylates are the essential treatment for inflammatory bowel diseases (IBDs), which have also been used for the prevention and treatment of RE for more than 50 years (Rauch and Weiland, 1972; Cai et al., 2021). Among them, sulfasalazine (SASP) and 5-aminosalicylic acid (5-ASA) are the most frequently prescribed agents for symptom control in ARE. However, the effectiveness of aminosalicylates in ARE remains controversial. In a 1993 randomized trial, Baughan et al. (1993) found that 5-ASA increased the incidence of diarrhea in the patients who received pelvic radiotherapy compared with placebo, raising concerns about its therapeutic role. Subsequent randomized controlled trials (RCTs) yielded conflicting results, with some studies finding that 5-ASA failed to alleviate symptoms of RE (Martenson et al., 1996; Resbeut et al., 1997; Sanguineti et al., 2003). Furthermore, discrepancies exist regarding the efficacy of SASP. While Miller et al. (2016) observed no significant reduction in diarrhea, abdominal pain, hematochezia, or tenesmus with SASP treatment, two other RCTs (Kilic et al., 2000; Pal et al., 2013) reported a lower incidence of diarrhea in SASP-treated patients compared with placebo.

These inconsistencies in prior studies may be attributed to differences in study design, patient populations, radiation dosages, and drug regimens. Additionally, variations in outcome definitions and assessment criteria further complicate the interpretation of results. Given these uncertainties, a comprehensive meta-analysis is warranted to systematically evaluate the clinical efficacy of aminosalicylates (SASP and 5-ASA) in preventing and treating ARE.

Materials and methods

Eligibility

RCTs comparing SASP and 5-ASA with placebo or control drugs for relieving the clinical symptoms of ARE were included in this meta-analysis. The studies had to report data on clinical efficacy and/or adverse events. To ensure comprehensive coverage and convenience, only studies published in English or Chinese were included. Animal studies were excluded. Additionally, studies were excluded if they were duplicate publications, had incomplete data, contained missing data, exhibited statistical errors, or assessed efficacy without using standardized criteria.

Information sources and search

Eligible studies were searched in Pubmed, The Cochrane Library, Embase and Web of Science for publications dated before January 2020. The systematic search was performed with the following terms "5-aminosalicylate," "5-aminosalicylic acid," "5-ASA," "sulfasalazine," "SASP," "radiation enteritis," "radiation proctocolitis," "radiotherapy," "RE," and "enteritis". The terms were grouped in different combinations to search across different databases. For articles without full text, we contacted the authors to obtain the study details.


Study selection

The titles and abstracts of the identified studies were reviewed. Potentially eligible articles were collected for full-text review. In cases where there were disagreements about inclusion, discussions were held, and if necessary, a third reviewer was consulted to make the final decision.

Data extraction and quality assessment

General data from the eligible studies were collected independently by two researchers, including the name of the first author, year of publication, study type, primary disease, radiation dose, number of participants, participants' age and gender, form and dose of the drug, therapeutic approach and duration, as well as the incidence of total diarrhea, mild to moderate diarrhea, severe diarrhea, abdominal pain, constipation, hematochezia, and tenesmus. Adverse events and follow-up time were also recorded. If any of the aforementioned data were unavailable (NA), it was noted as NA. Since most of the included studies were randomized controlled trials, the quality was assessed based on the methods outlined in the Cochrane 5.1.0 handbook (Higgins et al., 2011), considering factors such as randomization, blinding, complete reporting, and other potential biases.

The Cochrane Risk of Bias tool is widely used for quality assessment in RCT studies. The assessment items include: generation of random sequences, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other biases. In the Cochrane quality assessment, if all items are rated as "low risk," the likelihood of various biases is minimized, and the overall score is rated as Grade A, indicating a high-quality study. If one or more items are rated as "unclear," there is a moderate possibility of corresponding biases, and the overall score is rated as Grade B, indicating a medium-quality study. If one or more items are rated as "high risk," the likelihood of corresponding biases is high, and the overall score is rated as Grade C, indicating a lowquality study.



Statistical analysis

The efficacy of aminosalicylates was evaluated according to the incidence of diarrhea, abdominal pain, constipation, hematochezia, and tenesmus. Additionally, the different forms and doses of the drug, therapeutic approach, and duration were also recorded. The relative risk (RR) was used as the combined statistic, and the Z-test was employed to obtain the probability P-value. If P < 0.05, the difference in efficacy between the two groups was considered statistically significant. If P > 0.05, the difference in efficacy was considered not statistically significant. The included study data were summarized, and subgroup analyses were conducted based on the type and dosage of ASA agents to compare the effects of different drug types and dosages on efficacy. The meta-analysis of included studies was conducted using the Review manager 5.3 software. The inconsistency value (I²) was calculated to assess heterogeneity between eligible trials. A random-effects model or subgroup analysis was applied if the heterogeneity was significant (P < 0.1, I²>50%). Otherwise, the fixed effect model was used. The Z-test was performed with relative RR to synthesize statistics across the trials. The difference was considered statistically significant while P < 0.05. Funnel plots were employed to detect potential publication bias.

Results

Study selection and baseline characteristics

A total of 321 relevant studies were obtained from the databases with searching terms described above. Of these, 314 studies were excluded for not meeting the inclusion criteria. Seven studies were included for meta-analysis (Baughan et al., 1993; Martenson et al., 1996; Resbeut et al., 1997; Sanguineti et al., 2003; Miller et al., 2016; Kiliç et al., 2000; Pal et al., 2013). They were randomized, doubleblinded controlled trials with well described inclusion and exclusion criteria. The use of drugs was described in detail. Except for an uncompleted study, other studies had comprehensive research data. The workflow of study selection was shown in Figure 1. The baseline characteristics were summarized in Table 1. A total of 613 patients were included in the 7 studies, in which 279 patients were treated with aminosalicylates, 278 with placebo and 56 with sucralfate. The age, sex and radiation dose were comparable among these groups (Table 1).

Efficacy of aminosalicylates on relieving symptoms of radiation enteritis

Diarrhea

In the seven studies, the primary endpoint was the maximum severity of diarrhea for each patient. The incidence of total diarrhea did not differ significantly between the aminosalicylates and control groups (68.5% vs. 72.2%; Q = 27.37, I² = 78.1%, P = 0.000; Z = 0.28, P = 0.78; Figure 2A). The incidence of mild to moderate diarrhea (grade I and II)in the aminosalicylates group was significantly lower than that in the control group (46.2% vs. 54.2%; Q = 8.04, I² = 25%, P = 0.23; Z = 2.90, P = 0.004; Figure 2B). In contrast, the incidence of severe diarrhea (grade III and IV) in the aminosalicylates group was similar to that in the control group (22.2% vs. 18.0%; Q = 23.39, I² = 74%, P = 0.001; Z = 0.95, P = 0.34; Figure 2C).

These results indicated that aminosalicylates could reduce the incidence of mild to moderate diarrhea in the ARE patients. However, it may not be effective in relieving severe diarrhea.

In addition, the proportion of patients using anti-diarrhea medications in the aminosalicylates group was significantly higher than that in the control group (52.6% vs. 27.5%) in two studies (Q = 0.21, $I^2 = 0\%$, P = 0.65; Z = 3.07, P = 0.002; Figure 2D).

Abdominal pain

Three studies evaluated the efficacy of aminosalicylates on relieving abdominal pain in patients with ARE. The results showed that the incidence of abdominal pain was similar between the aminosalicylates and the control groups (41.8% vs. 43.6%; Q = 7.35, I² = 73%, P = 0.03; Z = 0.24, P = 0.81; Figure 3A). This suggests that aminosalicylates may not reduce the incidence of abdominal pain.

TABLE 1 Characteristic of Studies included in the Meta-Analysis.

		i staares metaaca								
No.	1st author year	Journal	Study type	Numbers of patients in Total/Group a/ Group b	Radiation dosage (Gy)	Tumor types (cases)	Group a	Group b	Duration of use	Other treatments
1	Miller (2016)	Int J Radiat Oncol Biol Phys	RCT	Total:N = 84; 37-84y Group a: n = 42 Group b: n = 42	45.0-53.0 or >53.0	Colorectal cancer (51) Gynecological tumor (16) Prostate carcinoma (15) Pelvic tumor (1) Others (1)	Oral Sulfasalazine (2.0 g/d)	Placebo	During radiotherapy to 4 weeks after radiotherapy	Fluorouracil Capecitabine Oxaliplation
2	Pal (2013)	Clin Cancer Invest J	RCT	Total:N = 95; 35–70y Group a: n = 47 Group b: n = 48	50.0	Gynecological tumor (95)	Oral Sulfasalazine (2.0 g/d)	Placebo	During radiotherapy to 1 week after radiotherapy	Cisplatinum
3	Sanguineti (2003)	Strahlenther Onkol	RCT	Total:N = 64; 52–89y Group a: n = 8 Group b: n = 56	76.0	Prostate carcinoma (64)	Mesalazine enemas (4.0 g/d)	Sucralfate enemas	During radiotherapy	No
4	Kilic (2000)	Radiother Oncol	RCT	Total: N = 87 Group a: n = 44; 59y Group b: n = 43; 61y	46-50	Colorectal cancer (42) Gynecological tumor (22) Urologic neoplasms (22) Pelvic sarcoma (1)	Oral Sulfasalazine (2.0 g/d)	Placebo	During radiotherapy	No
5	Resbeut (1997)	Radiother Oncol	RCT	Total: N = 153 Group a: n = 74; 64y Group b: n = 79; 62.8y	45-52	Prostate carcinoma (99) Gynecological tumor (54)	Oral Mesalazine (4.0 g/d)	Placebo	During radiotherapy	No
6	Martenson (1996)	Int J Radiat Oncol Biol Phys	RCT	Total: N = 58 Group a: n = 30; 69y Group b: n = 28; 70y	45-53.5	Colorectal cancer (5) Gynecological tumor (9) Urologic neoplasms (44)	Oral Olsalazine (1.0 g/d)	Placebo	During radiotherapy	Fluorouracil Levamisole

(Continued on following page)

No.	1st author year	Journal	Study type	Numbers of p Total/Group Group b		Radiatio dosage		Tumor (cases)	types	Group a		Group b	Duration of use	Other treatments
7	Baughan (1993)	Clin Oncol	RCT	Total: N = 72 Group a: n = 34; N Group b: n = 38; N		30-60		Urologic 1 (55) Gynecolog tumor (15 Colorectal cancer (2)	gical)	Oral Mesala (2.4 g/d)	zine	Placebo	1 day before radiotherap 4 weeks after radiothera	
No.	Clinical grading standards	Incidend total diarrhea	n (%) n	ncidence of nild-to- noderate liarrhea (%)	Incidence severe diarrhea (Rate of antidiari medicat (%)	rheal	Incide abdon pain (%	ninal		lence of stipation	Incidence of hematochezia (%)	Incidence of tenesmus (%)
1	CTCv4.0	Group a: 76 Group b: 76		roup a: 50.0 roup b: 66.7	Group a: 26.2 Group b: 9.5		Group a: 50 Group b: 28		Group a: Group b:		1	a: 38.1 b: 35.7	Group a: 38.1 Group b: 47.6	Group a:35.7 Group b:28.6
2	CTCv4.0	Group a: 44 Group b: 75		roup a: 40.4 roup b: 58.3	Group a: 4.3 Group b: 16.7		N/A		N/A		N/A		N/A	N/A
3	RTOG	Group a: 87 Group b: 62		roup a: 25.0 roup b: 26.8	Group a: 62.5 Group b: 35.7		N/A		N/A		N/A		N/A	N/A
4	Lent-soma	Group a: 54 Group b: 86		roup a: 47.7 roup b: 55.8	Group a: 6.8 Group b: 30.2		N/A		N/A		N/A		N/A	N/A
5	WHO	Group a: 70 Group b: 65		roup a: 56.8 roup b: 58.2	Group a: 13.5 Group b: 7.6		N/A		Group a: Group b:		N/A		N/A	N/A
6	CTC	Group a: 80 Group b: 75		roup a: 20.0 roup b: 60.7	Group a: 60.0 Group b: 14.3		N/A		Group a: Group b:		N/A		Group a: 26.7 Group b: 32.1	Group a:13.3 Group b:39.3
7	N/A	Group a: 91 Group b: 73		roup a: 52.9 roup b: 60.5	Group a: 38.2 Group b: 13.2		Group a: 55 Group b: 20		N/A			a: 32.4 b: 34.2	Group a: 8.8 Group b: 5.3	N/A

Group a: aminosalicylic acid group; Group b: control group; RCT, randomized controlled trial; N/A, data not available.

TABLE 1 (Continued) Characteristic of Studies included in the Meta-Analysis.


SS695-ASA Control Field Ratio Rel Ratio Baughan 1903 104 Pearly in 1744 1241 100, 1541 1993 Baughan 1903 21 22 174 52 74 52 Baughan 1903 21 22 174 52 74 52 74 52 74 52 74 52 74 52 74 52 74 52 74 55 74 74 55 65 13.0% 0.57 0.05 5 100 [07.8], 120] 104 74 66 60 0.001, P= 78.% 74 66 60 0.001, P= 78.% 74 66 60 0.001, P= 78.% 74 66 72 76 77 76 7									
Baughan 1983 Baughan 1983 Markenson 1996 24 30 21 28 142% 170 (98, 144) 1993 Research 1997 52 74 52 79 157% 107 (98, 144) 1996 Research 1997 52 74 52 79 157% 107 (98, 144) 1996 Pai 2013 21 44 37 43 138% 0.638 047, 063 2003 Pai 2013 21 44 7 36 44 12.4% 0.060 042, 063 2013 12 44 00 050 42, 063 2014 12 44 Miler 2016 21 22 42 32 42 15.2% 100 (0.7, 1.27) 2016 Total 69% C) 279 334 100.0% 0.97 [0.78, 1.20] Total 69% C) 279 334 100.0% 0.97 [0.78, 1.20] Total 69% C) 279 334 100.0% 0.97 [0.78, 1.20] SASP/5.ASA Control Risk Ratio Sasprise Ratio Risk Ratio Sasprise Ratio	Cturks or Cultureour								
	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year	M-H, Random, 95% Cl
Research 1997 52 74 52 79 157% 1.07 [0.86], 1.31 1997 Sangunet 2003 7 8 35 66 13.0% 1.03 [0.47, 0.68] 2003 Sangunet 2003 7 8 35 66 13.0% 1.04 [0.01, 4.16] 2003 Sangunet 2003 7 8 35 66 13.0% 1.04 [0.04, 0.69] 2013 Miller 2016 32 42 32 42 15.2% 1.00 [0.76, 1.27] 2016 Total 69% Ch 279 334 100.0% 0.97 [0.76, 1.20] 10.5% 5.38P/5.ASA Control Risk Ratio Stuby or Stubord Devetts Total 69% Ch 20 0.5 1.05% 0.31 [0.07] 1.65% 0.65 (1.2) 0.5% (1.2) Baughan 1993 18 34 23 38 1.05% 0.05 (1.5, 0.2) 1995 1.65% 0.65 (1.5, 0.2) 1995 Kilc 2000 21 44 24 1.45% 0.65 (1.5, 7.1.2) 1995 1.01 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.	Baughan 1993	31	34	28	38	15.7%	1.24 [1.00, 1.54]	1993	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Martenson 1996	24	30	21	28	14.2%	1.07 [0.81, 1.41]	1996	
Sangunet 2003 Pai 2013 Miler 2016 3 2 42 3 3 4 100.0% 0 87 [0.76, 1.20] Total events 191 241 Heterogeneity: Tat" = 0.7; Ch" = 27.37; d" = 6 (P = 0.001); P = 78% Test for overall effect Z = 0.20; Ch" = 27.37; d" = 6 (P = 0.001); P = 78% Test for overall effect Z = 0.20; Ch" = 27.37; d" = 6 (P = 0.001); P = 78% Test for overall effect Z = 0.20; Ch" = 27.37; d" = 6 (P = 0.001); P = 78% Test for overall effect Z = 0.20; Ch" = 27.37; d" = 6 (P = 0.001); P = 78% Test for overall effect Z = 0.20; Ch" = 27.37; d" = 6 (P = 0.001); P = 78% Test for overall effect Z = 0.20; Ch" = 27.37; d" = 6 (P = 0.001); P = 78% Test for overall effect Z = 0.20; Ch" = 27.37; d" = 6 (P = 0.001); P = 78% Test for overall effect Z = 0.20; P = 0.001 Total events 193 19 34 19 37; 28 49 16.5% 190 Total events 190 Total events 190 191 193 193 19 34 193 19 34 193 19 34 19 34 100.0% 0.79 [0.68, 0.33] 190 190 191 192 193 193 19 19 194 193 19 194 195 194 195 194 195 194 195 194 195 195 195 195 195 195 195 195	Resbeut 1997	52	74	52	79	15.7%	1.07 [0.86, 1.33]	1997	_
Sangunet 2003 Pai 2013 Miler 2016 3 2 42 3 3 4 100.0% 0 87 [0.76, 1.20] Total events 191 241 Heterogeneity: Tat" = 0.7; Ch" = 27.37; d" = 6 (P = 0.001); P = 78% Test for overall effect Z = 0.20; Ch" = 27.37; d" = 6 (P = 0.001); P = 78% Test for overall effect Z = 0.20; Ch" = 27.37; d" = 6 (P = 0.001); P = 78% Test for overall effect Z = 0.20; Ch" = 27.37; d" = 6 (P = 0.001); P = 78% Test for overall effect Z = 0.20; Ch" = 27.37; d" = 6 (P = 0.001); P = 78% Test for overall effect Z = 0.20; Ch" = 27.37; d" = 6 (P = 0.001); P = 78% Test for overall effect Z = 0.20; Ch" = 27.37; d" = 6 (P = 0.001); P = 78% Test for overall effect Z = 0.20; Ch" = 27.37; d" = 6 (P = 0.001); P = 78% Test for overall effect Z = 0.20; P = 0.001 Total events 193 19 34 19 37; 28 49 16.5% 190 Total events 190 Total events 190 191 193 193 19 34 193 19 34 193 19 34 19 34 100.0% 0.79 [0.68, 0.33] 190 190 191 192 193 193 19 19 194 193 19 194 195 194 195 194 195 194 195 194 195 195 195 195 195 195 195 195			44	37	43				
Pai 2013 21 47 38 48 12.4% 0.60[0.42, 0.65] 2013 Miler 2016 32 42 32 42 15.2% 1.00[0.78, 1.27] 2016 Total events 191 241 Heterogenety: Tau* = 0.7; Ch* = 27.37, df= 6 (P = 0.001); P = 78% Test for overall effect. Z = 0.28 (P = 0.78) SASP/5-ASA Control Risk Ratio Reskeu 1997 42 74 46 79 26.6% 0.07[10.4], 129 1997 Materison 1996 6 30 17 22 81 15 56 2.2% 0.39[10.5, 0.7] 1993 Materison 1996 15 30 17 22 81 15 56 2.2% 0.39[10.5, 0.7] 1997 Materison 1996 15 30 17 22 81 15 56 2.2% 0.39[10.5, 0.7] 1997 Materison 1996 15 30 17 22 81 15 56 2.2% 0.39[10.5, 0.7] 1997 Miler 2016 21 42 22 84 21 16.7% 0.75[0.52, 1.09] 2015 Total events 129 181 Heterogenetic, Ch* = 0.4, df= 6 (P = 0.03); P = 75% Total events 129 181 Heterogenetic, Ch* = 0.4, df= 6 (P = 0.03); P = 75% Total events 129 181 Heterogenetic, Ch* = 0.4, df= 6 (P = 0.03); P = 75% Total events 129 181 Heterogenetic, Ch* = 0.4, df= 6 (P = 0.007); P = 74% Materison 1996 11 30 4 22 14 48 10.9% 0.28 [0.6], 1.42 [1997 Kilic 2000 2 44 13 43 131% 0.28 [0.0] C, 74 [200 SASP/5-ASA Control Risk Ratio Study or Subarcoup Events Total Events Total Weight MH, Random, 55% Cl Year Materison 1996 18 30 4 28 14.9% 4.20 [1.62, 1.08] 1993 Materison 1996 11 30 4 13 43 131% 0.28 [0.0, 74] 2003 Pal 2013 2 47 8 48 10.9% 0.28 [0.6], 1.42 2013 Pal 2013 2 47 8 48 10.9% 0.28 [0.6], 1.42 2013 Pal 2013 2 47 8 48 10.9% 0.28 [0.6], 1.42 2013 Pal 2013 2 47 8 48 10.9% 0.28 [0.6], 1.42 2013 Pal 2013 2 47 8 48 10.9% 0.28 [0.6], 1.42 2013 Pal 2013 2 47 8 48 10.9% 0.28 [0.6], 1.42 2013 Pal 2013 2 47 8 48 10.9% 0.28 [0.6], 1.42 2013 Pal 2013 2 47 8 48 10.9% 0.28 [0.6], 1.42 2013 Pal 2013 2 47 8 48 10.9% 0.28 [0.6], 1.42 2013 Pal 2013 2 47 8 48 10.9% 0.28 [0.6], 1.42 2013 Pal 2013 2 27 75 0.57, 1.57 (1.57 0.98, 3.08] 2016 Total (95% Cl) 279 334 100.0% 1.43 [0.68, 2.97] Total events 62 Favours [SASP/5-ASA] Favours [Control] SASP/5-ASA Control Risk Ratio Favours [SASP/5-ASA] Favours [Control] SASP/5-ASA Control Risk Ratio Favours [SASP/5-ASA] Favours [Control] SASP/5-A									
Niller 2016 32 42 32 42 15 2% 1.00 [0.76, 1.27] 2016 Total (95% CI) 279 334 100.0% 0.97 [0.76, 1.20] Total (95% CI) 237, 37, df= 6 (P = 0.0001), P = 78% 2.01 Pavours [9ASP/5.ASA] Favours [0ASP/5.ASA]									
Total (95% CI) 279 334 100.0% 0.97 (0.78, 1.20) Total events 191 241 Heterogeneity: Tar' = 0.07; Chi ⁺ = 27.37; df = 6 (P = 0.0001); P = 78% Test for overall effect Z = 0.28 (P = 0.78) SASP/5-ASA Control Risk Ratio Risk Ratio Study of Subgroup Peersts Total Events Total events 100 (P = 0.0001); P = 78% Sasp15-ASA Control Risk Ratio Risk Ratio Risk Ratio Martenson 1996 6 30 17 28 15 56 2.2% 0.33 (0.15, 0.72) 1996 Pai 2013 19 47 28 15 56 2.2% 0.39 (0.26, 3.34) 100.0% 0.79 (0.68, 0.93) Total events 192 18 34 15 56 2.2% 10.1% Pavours (SASP/5-ASA Favours (Control) Sasph5 ASA Control Risk Ratio Risk Ratio Risk Ratio Risk Ratio Risk Ratio Study or Subgroup 193 13 34 10.0% 0.79 (0.68, 0.93) 10.1 10.1 10.1 10.1 Study or Subgroup							and the second		
Total events 191 241 Heterogeneity, Turz e 0.07; ChF = 27.37; df = 6 (P = 0.0001); P = 78% Test for overall effect Z = 0.28 (P = 0.76) SASP/5-ASA Control Risk Ratio Study of Subgroup Cents Total Vecint MH, Fixed, 95%; Cl Year MH, Fixed, 95%	Willer 2010	32	42	32	42	10.2%	1.00 [0.79, 1.27]	2010	
Heterogeneity: Tau"= 0.07; Chr = 27.37, df = 6 (P = 0.0001); P = 78% Test for overall effect Z = 0.28 (P = 0.78) SASP/5-ASA Control Risk Ratio Study of Subgroup Forms Total Venith MH, Fixed, 95% CI Year MH, Fixed, 95% CI Parours [SASP/5-ASA] Favours [Control] Martenson 1996 6 30 17 28 10.5% 0.33 [0.15, 0.72] 1993 Martenson 1996 6 30 17 28 10.5% 0.33 [0.15, 0.72] 1993 Martenson 1996 7 42 74 46 79 26.6% 0.497 [0.47, 1.28] 1997 Year Value of the tau of the tau of the tau of			279		334	100.0%	0.97 [0.78, 1.20]		•
Test for overall effect Z = 0.28 (P = 0.78) U2 2 Control Risk Ratio SASP/5-ASA Control Risk Ratio Subtrop Control Risk Ratio Martenson 1996 A 34 10/2 Risk Ratio Martenson 1996 Risk Ratio Martenson 1996 Risk Ratio Martenson 1996 Risk Ratio Resbeut 1997 42 7 A 15 56 Risk Ratio									
Test for overall effect $2 = 0.28$ ($P = 0.78$) Favours [SASP/5-ASA Favours [Control] SASP/5-ASA Control Resker 1997 12 10.5% (C) Year MH, Fixed, 95% (C) Resker 1997 12 74 4 6 79 26.8% 0.37 (0.16, 0.132) 1993 Resker 1997 12 74 4 6 79 26.8% 0.97 (0.24, 1.28) 1997 Resker 1997 12 74 4 6 79 26.8% 0.97 (0.24, 1.28) 1997 Resker 1997 12 72 8 10.5% 0.96 [0.61, 1.29] 2010 Sangunet 2003 2 8 15 56 2.2% 0.93 (0.26, 3.34) 2003 Sangunet 2003 2 8 15 56 2.2% 0.93 (0.26, 3.34) 2003 Miller 2016 21 42 28 42 16.7% 0.75 (0.52, 1.09) 2016 Total effect 2 = 0.904) SASP/5-ASA Control Risk Ratio SASP/5-ASA Control Risk Ratio SASP/5-ASA Control Risk Ratio SASP/5-ASA Favours [Control] SASP/5-ASA Favours [Control] Saspunet 2003 5 8 20 65 17.2% 1.75 (0.92, 3.32) 2003 Sangunet 2003 5 8 20 65 61 7.2% 1.76 (0.92, 3.32) 2003 Miller 2016 11 42 4 42 14.0% 2.27 (0.95, 7.95 2016 Heterogeneity: Tat ² = 0.71; Chi ² = 2.3.9; dif = 6 (P = 0.0007); P = 74% Total events for 2 47 8 48 10.0% 0.28 (0.06, 1.41 2013 Miller 2016 21 42 12 42 56.0% 1.75 (0.92, 3.32) 2003 Miller 2016 21 42 12 42 56.0% 1.75 (0.92, 7.95 2016 MH, Fixed, 95% CI Total events for 2 40 MH, Fixed, 95% CI Favours [SASP/5-ASA] Favours [Control] Study or Subaroup Events Total Weight MH, Haved, 95% CI Year MH, Fixed, 95% CI Total events for 2 40 Heterogeneity: Tat ² = 0.71; Chi ² = 2.3.9; dif = 6 (P = 0.0007); P = 74% Total events for 2 40 Heterogeneity: Tat ² = 0.71; Chi ² = 2.3.9; dif = 6 (P = 0.0007); P = 74% Total events for 2 1 40 21 42 12 42 56.0% 1.75 (0.98, 7.95 2016 MH, Fixed, 95% CI Favours [SASP/5-ASA] Favours [Control] Favours [SASP/5-ASA] Favours [Control] Favours [SASP/5-ASA] Favours [Control] Favours [SA					' = 0.01	001); I ^z =	78%		
Study or Subgroup Events Total Events Total Weight M.H., Exed, 95% CI Baughan 1993 18 34 23 38 13.0% 0.67 (0.58, 1.32) 1993 Martenson 1996 6 30 17 28 10.5% 0.33 (0.15, 0.72) 1993 Resbeut 1997 42 7.4 46 79 26.6% 0.67 (0.58, 1.32) 1093 Sanguineti 2003 2 8 15 56 2.2% 0.63 (0.50, 7.12) 2003 Miller 2016 21 42 28 42 16.7% 0.75 (0.52, 1.09) 2016 Total events 129 181 100.0% 0.79 (0.68, 0.33) 100.1 10 10 Favours (SASP/5-ASA Control Risk Ratio Risk Ratio Risk Ratio Risk Ratio Risk Ratio Study or Subgroup Verents Total Verents Total 8.30 4.20 (1.56, 7.95 (2.10.89) 1993 Resbeut 1997 10 74 6 7.91 (4	Test for overall effect:	Z=0.28 (F	P = 0.78)					
Baughan 1993 18 34 22 38 13.0% 0.87 [0.5, 1.32] 1993 Matenson 1996 6 30 17 28 10.5% 0.37 [0.7,1 1.28] 1993 Kilic 2000 21 44 22 74 45 79 26.6% 0.97 [0.7,1 1.28] 1997 Kilic 2000 21 44 22 74 42 74 43 14.5% 0.86 [0.7,1 1.28] 2000 Sanguinel 2003 2 8 15 66 2.2% 0.33 [0.26, 3.4] 2003 Pal 2013 19 47 28 48 16.5% 0.69 [0.45, 1.06] 2013 Miller 2016 21 42 28 42 16.7% 0.75 [0.5, 1.09] 2016 Total 6% Ch 279 334 100.0% 0.79 [0.68, 0.93] Total events 129 181 Heterogeneity. Chi ² = 0.40, df = 6 (P = 0.23); P = 25% Test for overall effect. Z = 2.90 (P = 0.004) SASP/5-ASA Control Risk Ratio Study or Subgroup Events Total Events Total Weight MH, Random, 95% Cl Year Matenson 1996 18 30 4 28 14.9% 4.20 [1.6,7, 30] 1993 Matenson 1996 18 30 4 28 14.9% 4.20 [1.6,7, 1.29] 2003 Sanguinel 2003 5 8 20 56 17.2% 1.75 [0.92, 3.23] 2003 Fersebut 1997 10 74 6 79 14.8% 1.76 [0.88, 4.55] 1997 Total events 62 Baughan 1993 19 34 10 38 44.0% 2.275 [0.95, 7.95] 2016 Total (95% Ch) 279 334 100.0% 1.43 [0.68, 2.97] Total events 62 Baughan 1993 19 34 10 38 44.0% 2.12 [1.15, 3.91] 1993 Miller 2016 11 42 4 42 14.0% 2.75 [0.95, 7.95] 2016 Total (95% Ch) 279 334 100.0% 1.43 [0.68, 2.97] Total events 62 Baughan 1993 19 34 10 38 44.0% 2.12 [1.15, 3.91] 1993 Miller 2016 21 42 12 42 56.0% 1.75 [0.99, 3.08] 2016 Total (95% Ch) 76 8 10 10.0% 1.91 [1.27, 2.90] Miller 2016 21, 42 12 42 56.0% 1.75 [0.99, 3.08] 2016 Total (95% Ch) 76 8 10 10.0% 1.91 [1.27, 2.90] Miller 2016 21, 42 12 42 56.0% 1.75 [0.99, 3.08] 2016 Total (95% Ch) 76 8 10 00.0% 1.91 [1.27, 2.90] Miller 2016 21, 42 12 42 56.0% 1.75 [0.99, 3.08] 2016 Total (95% Ch) 76 8 10 10.0% 1.91 [1.27, 2.90] Miller 2016 21, 42 12 42 56.0% 1.75 [0.99, 3.08] 2016 Total (95% Ch) 76 8 10 10.0% 1.91 [1.27, 2.90] Miller 2016 21, 42 12 42 56.0% 1.75 [0.99, 3.08] 2016 Total (95% Ch) 76 8 10 10.0% 1.91 [1.27, 2.90] Miller 2015 21, 42 12 42 56.0% 1.75 [0.99, 3.08] 2016 Total (95% Ch) 76 8 10 10.0% 1.91 [1.27, 2.90] Miller 2015 0 7B (for aminosallcylate in relieving diarchea in patient		SASP/5	-ASA	Contr	ol		Risk Ratio		Risk Ratio
Baughan 1993 18 34 23 38 13.0% 0.37 [0.5, 1.32] 1993 Matenson 1996 6 30 17 28 10.5% 0.37 [0.74, 1.28] 1993 Kilic 2000 21 44 24 43 14.5% 0.36 [0.57, 1.29] 2000 Sanguinel 2003 2 8 15 65 2.2% 0.33 [0.26, 3.41 2000 Pal 2013 19 47 28 48 16.5% 0.59 [0.45, 1.06] 2013 Miller 2016 21 42 28 42 16.7% 0.75 [0.52, 1.09] 2016 Total 95% C) 279 334 100.0% 0.79 [0.68, 0.33] Total events 129 181 Heterogeneity. Chi ^P = 8.04, df = 6 (P = 0.23); P= 25% Test for overall effect. Z = 2.90 (P = 0.004) SASP/5-ASA Control Risk Ratio Study or Subgroup Events Total Weight MH, Faxed, 95% Cl Year MH, Random, 95% Cl Baughan 1993 13 34 5 38 15.1% 0.23 [0.7, 7.4] 2000 Sanguinet 2003 5 8 20 56 17.2% 1.78 [0.88, 4.59] 1995 Matenson 1996 18 30 4 4 28 14.9% 0.28 [0.66, 1.14] 2010 Feresbut 1997 10 74 6 79 14.8% 1.77 [0.52, 3.23] 2003 Sanguinet 2003 5 8 20 56 17.2% 1.75 [0.92, 3.23] 2003 Matenson 1996 11 42 4 42 14.0% 0.27 [0.68, 0.51] 1997 Total events 62 Baughan 1993 19 34 10 38 44.0% 0.28 [0.67, 7.4] 2000 SASP/5-ASA Control Risk Ratio Study or Subgroup Events Total Events Total Weight MH, Faxed, 95% Cl Year Baughan 1993 19 34 10 38 44.0% 2.12 [1.15, 3.91] 1993 Miller 2016 11 42 4 42 14.0% 2.75 [0.95, 7.95] 2016 Total (95% Cl) 279 334 100.0% 1.43 [0.68, 2.97] Total events 62 Baughan 1993 19 34 10 38 44.0% 2.12 [1.15, 3.91] 1993 Miller 2016 21 42 12 42 56.0% 1.75 [0.99, 3.08] 2016 Total (95% Cl) 76 8 10 10.0% 1.91 [1.27, 2.90] Miller 2016 11 42 4 22 Heterogeneity: Chi ^P = 0.21, df = 1 (P = 0.65); P = 0% Total events 40 22 Heterogeneity: Chi ^P = 0.21, df = 1 (P = 0.65); P = 0% Total events 40 22 Heterogeneity: Chi ^P = 0.21, df = 1 (P = 0.65); P = 0% Test for overall effect. Z = 3.07 (P = 0.002) HE 2 Events 5 of R R for aminosalle/state in relieving diarrhea in patients with ARE. (A) Total diarrhea. (B) Mild to moderate diarrhea. (C) Severe	Study or Subgroup	Events	Total	Events	Total	Weight	M-H. Fixed, 95% CI	Year	M-H. Fixed, 95% Cl
Marfanson 1996 6 30 17 28 10.5% 0.33 [0.15] 0.72] 1996 Resbeut 1997 42 74 46 79 26.5% 0.976 [0.74, 1.28] 1997 Kilk 2000 21 44 24 43 14.5% 0.86 [0.57, 1.29] 2000 Sanguineti 2003 2 8 15 66 2.2% 0.33 [0.26, 3.34] 2003 Pal 2013 19 47 28 48 16.5% 0.98 [0.45, 1.06] 2013 Miller 2016 21 42 28 42 16.7% 0.75 [0.52, 1.09] 2016 Total (95% CI) 279 334 100.0% 0.79 [0.68, 0.93] Total events 129 181 Heterogeneity: Chi ^P = 0.04, df = 6 (P = 0.23); P = 25% Test for overall effect Z = 2.90 (P = 0.004) Resbeut 1997 10 74 6 79 14.8% 17.8 [0.68, 4.65] 1997 Total events 103 13 34 5 38 15.1% 2.91 [1.16, 7.30] 1993 Amarenson 1996 18 30 44 13 413 131 % 0.23 [0.07, 0.74] 2000 Sanguineti 2003 5 8 20 56 17.2% 1.75 [0.92, 3.32] 2003 Sanguineti 2003 5 8 20 56 17.2% 1.75 [0.92, 3.32] 2003 Pal 2013 2 47 8 48 10.9% 0.26 [0.06, 1.14] 2013 Total (95% CI) 279 334 100.0% 1.43 [0.68, 2.97] Total events 120 .34 for 6 (P = 0.0007); P = 74% Test for overall effect Z = 0.95 (P = 0.34) Resbeut 1997 10 74 6 79 14.8% 0.28 [0.06, 1.14] 2013 Miller 2016 11 42 4 42 14.0% 2.175 [0.92, 3.32] 2003 Sanguineti 2003 5 8 20 56 07 .2% 1.75 [0.92, 3.32] 2003 Favours [SASP/5-ASA] Favours [Control] Study or Subarroup Events Total Weight M.H. Fixed, 95% CI Year Heterogeneity, Tau ² = 0.71 (ch ² = 2.39, df = 6 (P = 0.0007); P = 74% Total (95% CI) 279 334 100.0% 1.43 [0.68, 2.97] Total events 62 60 Heterogeneity, Tau ² = 0.71 (ch ² = 2.39, df = 6 (P = 0.0007); P = 74% Total (95% CI) 76 80 100.0% 1.43 [0.68, 2.97] Total events 40 22 Heterogeneity, Tau ² = 0.71, (ch ² = 2.39, ff = 6 (P = 0.0007); P = 74% Total (95% CI) 76 80 100.0% 1.91 [1.27, 2.90] Miller 2016 21 42 12 42 56.0% 1.75 [0.99, 3.08] 2016 Total (95% CI) 76 80 100.0% 1.91 [1.27, 2.90] Miller 2016 21, df = 1 (P = 0.65); P = 0% Test for overall effect Z = 3.07 (P = 0.002) Het 2 Heterogeneity, Chi ^P = 0.21, df = 1 (P = 0.65); P = 0% Test for overall effect Z = 3.07 (P = 0.002) Het 2 Heterogeneity Chi ^P = 0.21, df = 1 reliving diarchea in patients with ARE. (A) Total									
Sespent 1997 42 74 46 79 26.6% 0.37 [0.74, 1.29] 1997 Kille 2000 21 44 24 43 14.5% 0.38 [0.57, 1.29] 2000 Sanguineti 2003 2 8 15 56 2.2% 0.33 [0.26, 3.34] 2003 Pal 2013 19 47 28 48 16.5% 0.58 [0.57, 1.29] 2003 Pal 2016 21 42 28 42 16.7% 0.57 [0.52, 1.09] 2016 Total (95% Ch) 279 334 100.0% 0.79 [0.68, 0.93] 101 10 Festoroverall effect Z = 2.90 (P = 0.004) P25% Total (95% Ch) 279 334 100.0% 0.79 [0.68, 0.93] Study or Subaroup Events Total Events Total (95% Ch) 2.99 [1.16, 7.30] 1093 Resbeut 1997 10 74 6 79 14.8% 1.78 [0.68, 4.65] 1997 Study or Subaroup Events Total (95% Ch) 279 334 100.0% 2.75 [0.95, 7.95] 2016 Total events 62 63 11<									_
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $									
Sanguineti 2003 2 8 8 15 56 2.2% 0.83 [0.26; 3.34] 2003 Pal 2013 19 47 28 48 16.5% 0.69 [0.45, 1.06] 2013 Total (95% C) 279 334 100.0% 0.79 [0.68, 0.93] Total events 129 181 Heterogeneity: Chf = 8.04, d1 = 6 (P = 0.23); P = 25% Test for overall effect Z = 2.90 (P = 0.004) SASP/5-ASA Control Risk Ratio Study or Subaroup Events Total Events Total Weight MH, Random, 95% CI Year Male ratio 199 11 42 42 42 14.9% 4.20 [1.62, 1.08] 1993 Martenson 1996 18 30 4 28 14.9% 4.20 [1.62, 0.83] 1996 Resbeut 1997 10 74 6 79 14.8% 1.78 [0.84, 455] 1997 Heterogeneity: Tau ² = 0.71; Chi ² = 23.39, df = 6 (P = 0.0007); P = 74% Total events 62 60 Heterogeneity: Tau ² = 0.71; Chi ² = 23.39, df = 6 (P = 0.0007); P = 74% Total events 62 60 Heterogeneity: Tau ² = 0.71; Chi ² = 23.39, df = 6 (P = 0.0007); P = 74% Total events 40 22 Heterogeneity: Chi ² = 0.21, df = 1 (P = 0.65); P = 0% Total effect Z = 3.07 (P = 0.002) Heterogeneity: Chi ² = 0.21, df = 1 (P = 0.65); P = 0% Total effect Z = 3.07 (P = 0.002) Heterogeneity: Chi ² = 0.21, df = 1 (P = 0.65); P = 0% Test for overall effect Z = 3.07 (P = 0.002) Heterogeneity: Chi ² = 0.21, df = 1 (P = 0.65); P = 0% Test for overall effect Z = 3.07 (P = 0.002) Heterogeneity: Chi ² = 0.21, df = 1 (P = 0.65); P = 0% Test for overall effect Z = 3.07 (P = 0.002) Heterogeneity: Chi ² = 0.21, df = 1 (P = 0.65); P = 0% Test for overall effect Z = 3.07 (P = 0.002) Heterogeneity: Chi ² = 0.21, df = 1 (P = 0.65); P = 0% Test for overall effect Z = 3.07 (P = 0.002) Heterogeneity: Chi ² = 0.21, df = 1 (P = 0.65); P = 0% Test for overall effect Z = 3.07 (P = 0.002) Heterogeneity: Chi ² = 0.21, df = 1 (P = 0.65); P = 0% Test for overall effect Z = 3.07 (P = 0.002) Heterogeneity: Chi ² = 0.21, df = 1 (P = 0.65); P = 0% Test for overall effect Z = 3.07 (P = 0.002) Heterogeneity: Chi ² = 0.21, df = 1 (P = 0.65); P = 0% Test for overall effect Z = 3.07 (P = 0.002) Heterogeneity: Chi ² = 0.21, df = 1 (P = 0.65); P = 0% Test for overall effect Z = 3.07 (P =									
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $									
Miller 2016 21 42 28 42 16.7% 0.75 [0.52, 1.09] 2016 Total (95% CI) 279 334 100.0% 0.79 [0.68, 0.93] 101 Total (95% CI) 279 131 100.0% 0.79 [0.68, 0.93] Heterogeneity: Ch ² = 0.3 (h ² = 6 (P = 0.23); P = 25% Test for overall effect Z = 2.90 (P = 0.004) Risk Ratio Risk Ratio Study or Subgroup Events Total Vecint HL, Random, 95% CI Year Baughan 1993 13 34 5 38 15.1% 2.91 [1.16, 7.30] 1993 Martenson 1996 18 30 4 28 13.1% 0.22 [10.02, 10.89] 1996 Resbeut 1997 10 74 6 79 14.8% 1.78 [0.68, 4.55] 1997 Sanguineti 2003 5 8 20 56 17.2% 1.75 [0.92, 3.32] 2016 Total (95% CI) 279 334 100.0% 1.43 [0.68, 2.97] 101 10 101 Favours [Control] Risk Ratio Risk Ratio Risk Ratio Risk Ratio Risk Ratio Total (95% CI) 279 33	-								
Total (95% Cl) 279 334 100.0% 0.79 [0.68, 0.93] Total events 129 181 Heterogeneity: Ch ² = 8.04, df = 6 (P = 0.23); P = 25% 0.01 0.1 </td <td>Pal 2013</td> <td>19</td> <td>47</td> <td>28</td> <td>48</td> <td>16.5%</td> <td>0.69 [0.45, 1.06]</td> <td>2013</td> <td></td>	Pal 2013	19	47	28	48	16.5%	0.69 [0.45, 1.06]	2013	
Total events 129 181 Number of the second se	Miller 2016	21	42	28	42	16.7%	0.75 [0.52, 1.09]	2016	
Heterogeneily: Chi ^P = 8.04, df = 6 (P = 0.23); P = 25% Test for overail effect. Z = 2.90 (P = 0.004) SASP/5-ASA Control Risk Ratio Study or Subgroup SASP/5-ASA Control Risk Ratio Baughan 1993 13 34 5 38 15.1% 2.91 [1.16, 7.30] 1993 Martenson 1396 18 30 4 28 14.9% 4.20 [1.62, 10.89] 1996 Resbeut 1997 10 74 6 79 14.8% 1.75 [0.92, 3.32] 2003 Sanguineti 2003 5 8 20 56 17.2% 1.75 [0.92, 3.32] 2003 Sanguineti 2003 5 8 20 56 17.2% 1.75 [0.92, 3.32] 2003 Pai 2016 11 42 4 42 14.0% 2.75 [0.95, 7.95] 2016 Total (95% Cl) 279 334 100.0% 1.43 [0.68, 2.97] Total events 62 60 Heterogeneity: Tau ² = 0.71; Chi ^P = 23.39, df = 6 (P = 0.0007); P = 74% Test for overail effect. Z = 0.95 (P = 0.34) SASP/5-ASA Control Risk Ratio Study or Subgroup SASP/5-ASA Control Risk Ratio Study or Subgroup SASP/5-ASA Control Risk Ratio Study or Subgroup SASP/5-ASA Control Risk Ratio Total events 40 22 Heterogeneity: Chi ^P = 0.21, df = 1 (P = 0.65); P = 0% Total events 40 22 Heterogeneity: Chi ^P = 0.21, df = 1 (P = 0.65); P = 0% Total events 40 22 Heterogeneity: Chi ^P = 0.21, df = 1 (P = 0.65); P = 0% Total events 40 22 Heterogeneity: Chi ^P = 0.21, df = 1 (P = 0.65); P = 0% Total events 40 22 Heterogeneity: Chi ^P = 0.21, df = 1 (P = 0.65); P = 0% Total events 40 22 Heterogeneity: Chi ^P = 0.21, df = 1 (P = 0.65); P = 0% Total events 40 22 Heterogeneity: Chi ^P = 0.21, df = 1 (P = 0.65); P = 0% Total events 40 22 Heterogeneity: Chi ^P = 0.21, df = 1 (P = 0.65); P = 0% Total events 40 22 Heterogeneity: Chi ^P = 0.21, df = 1 (P = 0.65); P = 0% Total events 40 22 Heterogeneity: Chi ^P = 0.21, df = 1 (P = 0.65); P = 0% Total events 40 22 Heterogeneity: Chi ^P = 0.21, df = 1 (P = 0.65); P = 0% Test for overail effect. Z = 307 (P = 0.002) Heterogeneity: Chi ^P = 0.21, df = 1 (P = 0.65); P = 0% Test for overail effect. Z = 307 (P = 0.002) Heterogeneity: Chi ^P = 0.42, df = 1.02, df = 1	Total (95% CI)		279		334	100.0%	0.79 [0.68, 0.93]		•
Test for overall effect: $Z = 2.90$ (P = 0.004) Interpretation of the second s	Total events	129		181					
Test for overall effect: $Z = 2.90$ (P = 0.004) Events Total Events Total Weight M.H. Random, 95% CI Year Year Year Year Year Year Year Year	Heterogeneity: Chi ² =	: 8.04. df =	6(P = 0)	$(1.23): ^2 = 0$	25%				
Baughan 1993 13 34 5 38 15.1% 2.91 [1.16, 7.30] 1993 Martenson 1996 18 30 4 28 14.9% 4.20 [1.62, 1.08] 1996 Resbeut 1997 10 74 6 79 14.8% 1.78 [0.68, 4.65] 1997 Sanguineti 2003 5 8 20 56 17.2% 1.75 [0.93, 3.32] 2003 Pal 2013 2 47 8 48 10.9% 0.26 [0.06, 1.14] 2013 Miller 2016 11 42 4 42 14.0% 2.75 [0.35, 7.95] 2016 Total (95% Cl) 279 334 100.0% 1.43 [0.68, 2.97] 10 10 Total events 62 60 60 62 60 60 Heterogeneity: Tau ² = 0.71; Chi ² = 23.39, df = 6 (P = 0.0007); P = 74% Test for overall effect: Z = 0.95 (P = 0.34) 10 38 44.0% 2.12 [1.15, 3.91] 1993 Miller 2016 21 42 12 42 56.0% 1.75 [0.99, 3.08] 2016 Total events 40 22	1	SASP/5-	ASA	Contro	d		Risk Ratio		Risk Ratio
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	Year	M-H, Random, 95% Cl
Resbeut 1997 10 74 6 79 14.8% $1.78 [0.68, 4.65]$ 1997 Kilic 2000 3 44 13 43 13.1% 0.23 [0.07, 0.74] 2000 Sanguineti 2003 5 8 20 56 17.2% 1.75 [0.92, 3.32] 2003 Pal 2013 2 47 8 48 10.9% 0.28 [0.06, 1.14] 2013 Miller 2016 11 42 4 42 14.0% 2.75 [0.95, 7.95] 2016 Total (95% CI) 279 334 100.0% 1.43 [0.68, 2.97] 10 10 Test for overall effect: Z = 0.95 (P = 0.34) Total Events Total Events Total Events Total Events Total Weight M:H, Fixed, 95% CI Year M:H, Fixed, 95% CI Baughan 1993 19 34 10 38 44.0% 2.12 [1.15, 3.91] 1993 Miller 2016 21 42 12 42 56.0% 1.75 [0.99, 3.08] 2016 Total (95% CI) 76 80 100.0% 1.91 [1.27, 2.90] M:H, Fixed, 95% CI Total (95% CI)	Baughan 1993	13	34	5	38	15.1%	2.91 [1.16, 7.30]	1993	
Resbeut 1997 10 74 6 79 14.8% 1.78 [0.68, 4.65] 1997 Kilic 2000 3 44 13 43 13.1% 0.23 [0.07, 0.74] 2000 Sanguineti 2003 5 8 20 56 17.2% 1.75 [0.92, 3.32] 2003 Pal 2013 2 47 8 48 10.9% 0.26 [0.06, 1.14] 2013 Miller 2016 11 42 4 42 14.0% 2.75 [0.95, 7.95] 2016 Total (95% CI) 279 334 100.0% 1.43 [0.68, 2.97] 10.1 10 10 Festfor overall effect: Z = 0.95 (P = 0.34) Events Total Weight M-H, Fixed, 95% CI Year M-H, Fixed, 95% CI Baughan 1993 19 34 10 38 44.0% 2.12 [1.15, 3.91] 1993 Miller 2016 21 42 12 42 56.0% 1.75 [0.99, 3.08] 2016 Total (95% CI) 76 80 100.0% 1.91 [1.27, 2.90]	Martenson 1996	18	30	4	28	14.9%	4.20 [1.62, 10.89]	1996	
Kilic 2000 3 44 13 43 13.1% 0.23 [0.07, 0.74] 2000 Sanguineti 2003 5 8 20 56 17.2% 1.75 [0.92, 3.32] 2003 Pal 2013 2 47 8 48 10.9% 0.26 [0.06, 1.14] 2013 Miller 2016 11 42 4 42 14.0% 2.75 [0.95, 7.95] 2016 Total (95% CI) 279 334 100.0% 1.43 [0.68, 2.97] 100.01 0.1 10 Fest for overall effect: $Z = 0.95$ (P = 0.34) Events Total Events Total Events Total Events Total Events Total Weight M:H, Fixed, 95% CI Year Baughan 1993 19 34 10 38 44.0% 2.12 [1.15, 3.91] 1993 Miller 2016 21 42 12 42 56.0% 1.75 [0.99, 3.08] 2016 Total (95% CI) 76 80 100.0% 1.91 [1.27, 2.90] 0.05 0.2 5 20 Total (95% CI) 76 80 100.0%	Resbeut 1997	10	74	6	79	14.8%			
Sanguineti 2003 5 8 20 56 17.2% 1.75 [0.92, 3.32] 2003 Pal 2013 2 47 8 48 10.9% 0.26 [0.06, 1.14] 2013 Miller 2016 11 42 4 42 14.0% 2.75 [0.95, 7.95] 2016 Total (95% CI) 279 334 100.0% 1.43 [0.68, 2.97] Total events 62 60 60 60 100 100 Heterogeneity: Tau ² = 0.71; Chi ² = 23.39, df = 6 (P = 0.0007); I ² = 74% Note that the events Risk Ratio Risk Ratio Study or Subgroup Events Total Events Total Weight M.H., Fixed, 95% CI Year Baughan 1993 19 34 10 38 44.0% 2.12 [1.15, 3.91] 1993 Miller 2016 21 42 12 42 56.0% 1.75 [0.99, 3.08] 2016 Total (95% CI) 76 80 100.0% 1.91 [1.27, 2.90] 10.05 0.2 10.05 0.2 10.05 20 Total (95% CI) 76 80 100.0%									
Pai 2013 2 47 8 48 10.9% 0.26 [0.06, 1.14] 2013 Miller 2016 11 42 4 42 14.0% 2.75 [0.95, 7.95] 2016 Total (95% CI) 279 334 100.0% 1.43 [0.68, 2.97] Total events 62 60 Heterogeneity: Tau ² = 0.71; Chi ² = 23.39, df = 6 (P = 0.0007); P = 74% No.001 0.1 10 Test for overall effect: Z = 0.95 (P = 0.34) Control Risk Ratio Risk Ratio Study or Subgroup SASP/5-ASA Control Risk Ratio Risk Ratio Baughan 1993 19 34 10 38 44.0% 2.12 [1.15, 3.91] 1993 Miller 2016 21 42 12 42 56.0% 1.75 [0.99, 3.08] 2016 Total (95% CI) 76 80 100.0% 1.91 [1.27, 2.90] 93.08] 2016 Total events 40 22 Events 1.0 5 20 Heterogeneity: Chi ² = 0.21, df = 1 (P = 0.65); I ² = 0% 20 5 20 5 20 Total events 4									
Miller 2016114244214.0%2.75 $[0.95, 7.95]$ 2016Total (95% CI)279334100.0%1.43 $[0.68, 2.97]$ Total events6260Heterogeneity: Tau ² = 0.71; Chi ² = 23.39, df = 6 (P = 0.0007); I ² = 74% 1.43 $[0.68, 2.97]$ Test for overall effect: Z = 0.95 (P = 0.34)Risk RatioRisk RatioSASP/5-ASAControlRisk RatioRisk RatioStudy or SubgroupEventsTotalEventsTotalWeightM.H, Fixed, 95% CIYearM.H, Fixed, 95% CIBaughan 19931934103844.0%2.12 [1.15, 3.91]Miller 20162142124256.0%1.75 [0.99, 3.08]2016Total (95% CI)7680100.0%1.91 [1.27, 2.90]Total events4022Heterogeneity: Chi ² = 0.21, df = 1 (P = 0.65); I ² = 0%1.91 [1.27, 2.90]Total events4022Heterogeneity: Chi ² = 0.21, df = 1 (P = 0.002)1.91 [1.27, 2.90]JRE 2forest plots of RR for aminosalicylate in relieving diarrhea in patients with ARE. (A) Total diarrhea. (B) Mild to moderate diarrhea. (C) Severe	and a state of the second s								
Total (95% Cl)279334100.0%1.43 [0.68, 2.97]Total events 62 60 Heterogeneity: Tau ² = 0.71; Chi ² = 23.39, df = 6 (P = 0.0007); I ² = 74%Test for overall effect: Z = 0.95 (P = 0.34)Risk RatioSASP/5-ASAControlRisk RatioSasP/5-ASAControlRisk RatioSudy or SubgroupEventsTotal EventsTotal WeightM.H., Fixed, 95% ClBaughan 19931934103844.0%2.12 [1.15, 3.91]1993Miller 20162142124256.0%1.75 [0.99, 3.08]2016Total events4022Heterogeneity: Chi ² = 0.21, df = 1 (P = 0.65); I ² = 0%Test for overall effect: Z = 3.07 (P = 0.002)JRE 2e forest plots of RR for aminosalicylate in relieving diarrhea in patients with ARE. (A) Total diarrhea. (B) Mild to moderate diarrhea. (C) Severe									
Total events 62 60 Heterogeneity: Tau ² = 0.71; Chi ² = 23.39, df = 6 (P = 0.0007); I ² = 74%Test for overall effect: Z = 0.95 (P = 0.34)Risk RatioSudy or SubgroupSASP/5-ASAControlRisk RatioSudy or SubgroupEventsTotalEventsTotalBaughan 19931934103844.0%2.12 [1.15, 3.91]Baughan 19931934103844.0%2.12 [1.15, 3.91]Miller 20162142124256.0%1.75 [0.99, 3.08]2016Total (95% Cl)7680100.0%1.91 [1.27, 2.90]Total events4022Heterogeneity: Chi ² = 0.21, df = 1 (P = 0.65); I ² = 0%Test for overall effect: Z = 3.07 (P = 0.002)1.91 [1.27, 2.90]Favours [SASP/5-ASA] Favours [Control]	Willer 2016	11	42	4	42	14.0%	2.75 [0.85, 7.85]	2010	
Heterogeneity: Tau ² = 0.71; Chi ² = 23.39, df = 6 (P = 0.0007); I ² = 74% Test for overall effect: Z = 0.95 (P = 0.34)SASP/5-ASAControlRisk Ratio Risk RatioSudy or SubgroupSASP/5-ASAControlRisk RatioBaughan 19931934103844.0%2.12 [1.15, 3.91]1993Total Veight M-H, Fixed, 95% CIYearM-H, Fixed, 95% CIBaughan 19931934103844.0%2.12 [1.15, 3.91]1993Total (95% CI)7680100.0%1.91 [1.27, 2.90]Total (95% CI)7680100.0%1.91 [1.27, 2.90]Total (95% CI)7680100.0%1.91 [1.27, 2.90]Total (95% CI)7680100.0%1.91 [1.27, 2.90]Total (95% CI)7680100.0%1.91 [1.27, 2.90]0.050.2520Ference colspan="6">Second colspan="6">Second colspan="6">Second colspan="6">Colspan="6">Second colspan="6"Second colspan="6"Second colspan="6"Second colspan="6"S			279		334	100.0%	1.43 [0.68, 2.97]		◆
Test for overall effect: $Z = 0.95$ (P = 0.34)UU1UU1UU1UU1UU1IU1SASP/5-ASAControlRisk RatioSASP/5-ASAControlRisk RatioSASP/5-ASAControlRisk RatioSASP/5-ASAControlRisk RatioSudy or SubgroupEventsTotalFeventsTotalFeventsTotalFeventsTotal Weight M-H, Fixed, 95% ClYearM-H, Fixed, 95% ClBaughan 19931934103844.0%2.12 [1.15, 3.91]1993M-H, Fixed, 95% ClYearM-H, Fixed, 95% ClTotal (95% Cl)7680100.0%1.91 [1.27, 2.90]Total events4022Heterogeneity: Chi ² = 0.21, df = 1 (P = 0.65); P = 0.002)SubgroupSubgroupSubgroupColspan="6">SubgroupJRE 2e forest plots of RR for aminosalicylate in relieving diarrhea in patients with ARE. (A) Total diarrhea. (B) Mild to moderate diarrhea. (C) Severe						0.7.17	7.00		
Study or Subgroup Events Total Events Total Weight M-H, Fixed, 95% Cl Year M-H, Fixed, 95% Cl Baughan 1993 19 34 10 38 44.0% 2.12 [1.15, 3.91] 1993 Miller 2016 21 42 12 42 56.0% 1.75 [0.99, 3.08] 2016 Total (95% Cl) 76 80 100.0% 1.91 [1.27, 2.90]					' = U.UI	JU <i>T</i>); I*=	/4%		
Study or Subgroup Events Total Events Total Weight M-H, Fixed, 95% Cl Year M-H, Fixed, 95% Cl Baughan 1993 19 34 10 38 44.0% 2.12 [1.15, 3.91] 1993 Miller 2016 21 42 12 42 56.0% 1.75 [0.99, 3.08] 2016 Total (95% Cl) 76 80 100.0% 1.91 [1.27, 2.90] 0.05 0.2 1 5 20 Heterogeneity: Chi ² = 0.21, df = 1 (P = 0.65); P = 0.02) 76 80 100.0% 1.91 [1.27, 2.90] 76 5 20 Fastor overall effect: Z = 3.07 (P = 0.02) 76 80 100.0% 1.91 [1.27, 2.90] 76 5 20									
Baughan 1993 19 34 10 38 44.0% 2.12 [1.15, 3.91] 1993 Miller 2016 21 42 12 42 56.0% 1.75 [0.99, 3.08] 2016 Total (95% Cl) 76 80 100.0% 1.91 [1.27, 2.90] Total events 40 22 Heterogeneity: Chi ² = 0.21, df = 1 (P = 0.65); P = 0% 0.05 0.2 1 5 20 Test for overall effect: Z = 3.07 (P = 0.002) JRE 2 e forest plots of RR for aminosalicylate in relieving diarrhea in patients with ARE. (A) Total diarrhea. (B) Mild to moderate diarrhea. (C) Severe									
Miller 2016 21 42 12 42 56.0% 1.75 [0.99, 3.08] 2016 Total (95% Cl) 76 80 100.0% 1.91 [1.27, 2.90] Total events 40 22 Heterogeneity: Chi ² = 0.21, df = 1 (P = 0.65); P = 0% 0.05 0.2 1 5 20 Test for overall effect: Z = 3.07 (P = 0.002) VRE 2 e forest plots of RR for aminosalicylate in relieving diarrhea in patients with ARE. (A) Total diarrhea. (B) Mild to moderate diarrhea. (C) Severe	Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	Year	M-H, Fixed, 95% Cl
Total (95% Cl)7680100.0%1.91 [1.27, 2.90]Total events4022Heterogeneity: Chi² = 0.21, df = 1 (P = 0.65); P² = 0%Test for overall effect: $Z = 3.07$ (P = 0.002)JRE 2e forest plots of RR for aminosalicylate in relieving diarrhea in patients with ARE. (A) Total diarrhea. (B) Mild to moderate diarrhea. (C) Severe	Baughan 1993	19	34	10	38	44.0%	2.12 [1.15, 3.91]	1993	
Total events 40 22 Heterogeneity: Chi ² = 0.21, df = 1 (P = 0.65); I ² = 0% 0.05 0.2 1 5 20 Test for overall effect: Z = 3.07 (P = 0.002) Favours [SASP/5-ASA] Favours [Control] JRE 2 e forest plots of RR for aminosalicylate in relieving diarrhea in patients with ARE. (A) Total diarrhea. (B) Mild to moderate diarrhea. (C) Severe	Miller 2016	21	42	12	42	56.0%	1.75 [0.99, 3.08]	2016	
Total events 40 22 Heterogeneity: Chi ² = 0.21, df = 1 (P = 0.65); I ² = 0% 0.05 0.2 1 5 20 Test for overall effect: Z = 3.07 (P = 0.002) Favours [SASP/5-ASA] Favours [Control] JRE 2 e forest plots of RR for aminosalicylate in relieving diarrhea in patients with ARE. (A) Total diarrhea. (B) Mild to moderate diarrhea. (C) Severe	Total (95% CI)		76		80	100.0%	1.91 [1.27, 2.90]		-
Heterogeneity: Chi ² = 0.21, df = 1 (P = 0.65); l ² = 0% Image: the second secon		40		22	00				-
Test for overall effect: Z = 3.07 (P = 0.002) 0.05 0.2 1 5 20 Favours [SASP/5-ASA] Favours [Control] URE 2 e forest plots of RR for aminosalicylate in relieving diarrhea in patients with ARE. (A) Total diarrhea. (B) Mild to moderate diarrhea. (C) Severe			1 /P - 4		n 04.				
I est for overall effect: Z = 3.07 (P = 0.002) Favours [SASP/5-ASA] Favours [Control] URE 2 e forest plots of RR for aminosalicylate in relieving diarrhea in patients with ARE. (A) Total diarrhea. (B) Mild to moderate diarrhea. (C) Severe				<i>,</i> ,	0 70				0.05 0.2 1 5 20
JRE 2 e forest plots of RR for aminosalicylate in relieving diarrhea in patients with ARE. (A) Total diarrhea. (B) Mild to moderate diarrhea. (C) Severe	i est for overall effect	: Z = 3.07 ((P = 0.00	UZ)					
e forest plots of RR for aminosalicylate in relieving diarrhea in patients with ARE. (A) Total diarrhea. (B) Mild to moderate diarrhea. (C) Severe									a considerant Construction toward at the fider that a first data for
e forest plots of RR for aminosalicylate in relieving diarrhea in patients with ARE. (A) Total diarrhea. (B) Mild to moderate diarrhea. (C) Severe									
rrhea. (D) Incidence of using antidiarrheal medications.	URE 2								
		or aminosa	alicylate	in relievii	ng dia	rrhea in	patients with ARE. (A)	Total (diarrhea. (B) Mild to moderate diarrhea. (C) Severe

Constipation

Two studies evaluated the incidence of constipation in different groups of patients with ARE. The results showed that 35.5% (27/76) of the patients in the aminosalicylates group, and 35.0% (28/80) in the control group suffered constipation (Q = 0.07, $I^2 = 0.0\%$, P = 0.78; Z = 0.06, P = 0.96, Figure 3B). This suggests that aminosalicylates may not reduce the incidence of constipation.

Hematochezia

Three studies compared the incidence of hematochezia in different groups of patients with ARE. The results indicated that the incidence of hematochezia was similar between the aminosalicylates and the control groups (25.5% vs. 28.7%; Q = 0.66, I² = 0.0%, P = 0.72; Z = 0.70, P = 0.48; Figure 3C). This suggests that aminosalicylates may not reduce the incidence of hematochezia.



Tenesmus


Two studies analyzed the incidence of tenesmus in patients with ARE. Although there was a trend toward a decrease in the incidence of tenesmus in the aminosalicylates group, the difference was not statistically significant (26.4% vs. 32.9%; Q = 4.63, I² = 78%, P = 0.03; Z = 0.56, P = 0.58; Figure 3D). This suggests that aminosalicylates may not reduce the incidence of tenesmus.

Subgroup analysis

A subgroup analysis based on different types of aminosalicylate was conducted according to the efficacy on alleviating diarrhea. Although the incidence of total diarrhea was lower in the SASP group than that in the control group (57.9% vs. 78.9%; Q = 8.72, I² = 77%, P = 0.01; Z = 1.71, P = 0.09, Figure 4A), the difference was not significant. However, when we analyzed the data of mild to moderate diarrhea among these cases, a lower incidence was identified in the SASP group as

compared to the control group (45.9% vs. 60.2%; Q = 0.51, $I^2 = 0.0\%$, P = 0.78; Z = 2.30, P = 0.02; Figure 4B). Meanwhile, the incidence of severe diarrhea was similar in the SASP group as compared to the control group (12.0% vs. 18.8%; Q = 11.69, $I^2 = 83\%$, P = 0.003; Z = 0.65, P = 0.51; Figure 4C). These results suggest SASP may be beneficial to the ARE patients with mild to moderate diarrhea but not the severe cases.

The incidence of total diarrhea in the 5-ASA group was higher compared to the control group (78.1% vs. 67.7%; Q = 2.63, $I^2 = 0.0\%$, P = 0.45; Z = 2.40, P = 0.02; Figure 4A). For the incidence of mild to moderate diarrhea, the results were comparable between the two groups (46.6%vs. 50.2%; Q = 7.01, $I^2 = 57\%$, P = 0.07; Z = 1.24, P = 0.22; Figure 4B). However, 5-ASA significantly increased the incidence of severe diarrhea in the patients with ARE comparing to the control drugs (31.5% vs. 17.4%; Q = 2.99, $I^2 = 0.0\%$, P = 0.39; Z = 3.92, P = 0.000; Figure 4C). For this subgroup, 5-ASA did not show superiority, and may even aggravate diarrhea.



S-ASA subgroups). (B) Mild to moderate diarrhea (SASP and S-AS/ subgroups). (C) Severe diarrhea (SASP and S-ASA subgroups). (D) Total diarrhea (aminosalicylate ≤ 2 g/d and aminosalicylate > 2 g/ d subgroups).

Another subgroup analysis based on the dose of aminosalicylates was conducted. Seven studies were included. The incidence of diarrhea was comparable between the group treated with aminosalicylates ≤ 2 g/d and the control group (62.0% vs. 78.3%; Q = 12.72, $I^2 = 76\%$, P = 0.005; Z = 1.40, P = 0.16; Figure 4D). However, when the dose of aminosalicylates was escalated to ≥ 2 g/d, a higher incidence of diarrhea was reported in the aminosalicylates group comparing to the control group (77.6% vs. 66.5%; Q = 2.20, $I^2 = 9\%$, P = 0.33; Z = 2.35, P = 0.02, Figure 4D). These results indicated that low dose aminosalicylates may be safe while higher dose may worsen the symptoms of ARE.

Bias evaluation

Based on the assessment of publication bias by funnel plot, the RCTs analyzing different symptoms and treatments were basically symmetrical (Figures 5, 6). However, the numbers of RCTs included in each analysis were small, which may lead to publication bias.

Safety and adverse reactions


Some studies monitored and reported adverse events of aminosalicylates, most of which were vomiting, conjunctivitis, and skin rashes. However, the cause of the vomiting could not be determined since the patients were receiving chemoradiotherapy simultaneously.

Discussion

Studies had shown that the symptoms associated to ARE are primarily caused by gastrointestinal irritation and inflammation (Martenson et al., 1996). Radiotherapy induces the excessive production of oxygen radicals and inflammatory mediators, such as prostaglandins (PGs), leukotrienes (LTs), and thromboxanes (TXs) (Hubenak et al., 2014; Najafi et al., 2018). Aminosalicylates have been widely used in the treatment of inflammatory bowel disease (IBD) due to their anti-inflammatory and immunomodulatory effects. The pathogenesis of RE and IBD are similar to some extent. Aminosalicylates have been used to treat ARE in recent decades, but the efficacy has been controversial.

We conducted a meta-analysis to evaluate the efficacy of aminosalicylates in treating ARE, incorporating data from seven RCTs. The incidence of overall diarrhea was comparable between the aminosalicylate and control groups (68.5% vs. 72.2%, P > 0.05). However, in the aminosalicylates group, the incidence of mild-to-moderate diarrhea was significantly lower than in the control group (46.2% vs. 54.2%, P < 0.05), whereas the incidence of severe diarrhea remained similar between both groups (22.2% vs. 18.0%, P > 0.05). These findings suggest that while aminosalicylates do not significantly reduce the overall incidence of diarrhea or severe cases, they may be beneficial in alleviating mild-to-moderate diarrhea.

SASP was the first aminosalicylate introduced for IBD treatment (Cooke, 1969). SASP is a compound that includes 5-ASA and sulfapyridine (SP) which are connected by azo bond. The azo bonds in SASP and olsalazine are primarily cleaved by bacterial azo reductases in the ileum and colon, releasing the active component 5-ASA. Later studies found that the adverse effects of SASP were mainly attributable to SP. To mitigate these side effects, newer formulations such as olsalazine and mesalazine were developed, with mesalazine containing only 5-ASA. Olsalazine consists of two 5-ASA molecules linked by an azo bond. Most oral 5-ASA formulations are pH-dependent and release the drug in different sections of the intestinal tract. However, olsalazine and mesalazine have been reported to cause watery diarrhea in some IBD patients. This effect is thought to result from a concentrationdependent inhibition of Na + -K + -ATPase in the ileum and colon, reducing water and electrolyte absorption while increasing




secretion, ultimately leading to fluid overload in the colon (Scheurlen et al., 1993). Previous studies also found that osalazine and mesalazine increased the incidence of diarrhea in patients with pelvic radiotherapy (Martenson et al., 1996; Miller et al., 2016). Martenson et al. (1996) proposed that this adverse effect is similarly linked to Na + -K + -ATPase inhibition, which reduces ileal bile salt absorption and induces secretory diarrhea. However, some studies indicated that SASP could reduce the severity of diarrhea occurring in radiation (Kiliç et al., 2000; Pal et al., 2013).

We conducted a subgroup analysis for different pharmaceutical preparations of aminosalicylates. Our results showed that the incidence of overall and severe diarrhea was significantly higher in the 5-ASA group compared to the control group (78.1% vs. 67.7%, 31.5% vs. 17.4%, P < 0.05), while the SASP group exhibited lower diarrhea rates than the control group, though the difference was not statistically significant. Interestingly, SASP significantly reduced the incidence of mild-to-moderate diarrhea compared to the control group (45.9% vs. 60.2%, P < 0.05).

Previous studies have found that taking drugs containing prostaglandin may cause diarrhea (Barr and Naismith, 1972). Mennie et al. (1975) speculated that prostaglandin release might be a contributing factor in radiation-induced diarrhea. However, the differing effects of 5-ASA and SASP have led some researchers to question the precise role of eicosanoids in the pathogenesis of ARE. This has given rise to the hypothesis that 5-ASA and SASP may act through distinct mechanisms (Sanguineti et al., 2003). The failure of 5-ASA in treating ARE suggests that the sulfonamide component of SASP may be responsible for its diarrhea-reducing effects in ARE (Sanguineti et al., 2003).

Chemotactic peptide N-Formyl-L-methionyl-L-leucyl-Lphenylalanine (FMLP) is a bacteria-derived peptide that binds to a specific receptor on neutrophil, monocyte and macrophage, which leads to neutrophil chemotaxis and superoxide production (Cavicchioni et al., 2006). SASP has been shown to dosedependently inhibit FMLP binding to neutrophils and suppress FMLP-induced inflammation and chemotaxis, whereas 5-ASA exhibits a weaker effect (Stenson et al., 1984). The metabolites of LOX, cysteinyl leukotrienes (LTC4 and LTD4), can strongly increase the smooth muscle contractility and enhance mucus secretion and vascular permeability (Singh et al., 2010; Sasaki and Yokomizo, 2019). While SASP effectively inhibits the formation of these metabolites, 5-ASA exerts only a minimal effect (Nielsen et al., 1988).

Some studies found that the level of Thromboxane B2 (TXB2) was reduced and the colitis would be improved when the specific inhibitor to thrombin synthase, OKY1581, was given to the IBD patients (Vilaseca et al., 1990). Hawkey et al. (1985) found that SASP inhibited the production of TXB in the intestinal tissue homogenate induced by arachidonic acid, whereas 5-ASA has no such effect. Whether the above mentioned mechanisms can explain the



differences between 5-ASA and SASP in treating ARE needs further studies to validate.

Currently, no established consensus exists regarding the optimal dosage of aminosalicylates for ARE treatment. Previous studies (Kruis et al., 1998; Sann et al., 2013) indicate that different formulations may have varying effects on diarrhea. The aminosalicylate doses in our study ranged from 1 g/day to 4 g/ day. Our analysis revealed that the incidence of diarrhea was significantly higher in patients receiving aminosalicylates at doses >2 g/day compared to the control group (77.6% vs. 66.5%, P < 0.05). Prior research suggests that the watery diarrhea caused by olsalazine and mesalazine in IBD patients is dose-dependent (Scheurlen et al., 1993). Our findings align with these studies, indicating that using aminosalicylates at doses ≤ 2 g/day may be relatively safe in ARE.

Furthermore, our study found that aminosalicylates did not demonstrate superiority over control treatments in alleviating ARE symptoms such as abdominal pain, constipation, hematochezia, and tenesmus. Few adverse events were reported in these RCTs, and no severe adverse events were identified, suggesting that aminosalicylates are generally well-tolerated and safe. However, further evidence is needed due to variations in primary diseases, concurrent chemotherapy regimens, radiation doses, small sample sizes, and study heterogeneity within this meta-analysis.

A limitation of the included studies is that they relied solely on clinical symptoms to assess the severity of ARE. Incorporating endoscopy as an additional evaluation method would provide evidence regarding more objective the efficacy of aminosalicylates. Moreover, the use of antidiarrheal medications in some studies may have confounded the assessment of aminosalicylates' therapeutic effects in ARE. Additionally, none of the included studies evaluated or reported the prevalence of opportunistic infections, which could be an important consideration given the potential impact of immunosuppression or gut microbiota alterations in patients receiving aminosalicylates. Further randomized controlled trials are needed to validate their efficacy and assess the potential role of opportunistic infections in treatment outcomes.

Conclusion

In summary, SASP appears to be effective in preventing and treating mild to moderate diarrhea in ARE, while 5-ASA may be associated with an increased incidence of total and severe diarrhea in patients undergoing pelvic radiotherapy. A dosage of aminosalicylates ≤ 2 g/day is relatively safe for the treatment of ARE, whereas higher doses may worsen diarrhea. Given the limitations of this study, future well-designed randomized controlled trials with standardized dosing regimens and objective outcome measures are needed to further confirm the efficacy and safety of aminosalicylates in ARE.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding authors.

Author contributions

ZW: Data curation, Formal Analysis, Funding acquisition, Investigation, Methodology, Resources, Software, Visualization, Writing – original draft. CN: Data curation, Investigation, Methodology, Formal Analysis, Supervision, Writing – original draft. ZY: Supervision, Validation, Writing – original draft. ZX: Formal Analysis, Writing – original draft. LL: Formal Analysis, Writing – original draft. ZY: Formal Analysis, Writing – original draft. ST: Supervision, Writing – review and editing. YL: Supervision, Writing – original draft. WZ: Conceptualization, Project administration, Supervision, Writing – review and editing.

Funding

The author(s) declare that financial support was received for the research and/or publication of this article. This study was supported financially by Natural Science Foundation of Guangdong Province (No. 2017A030313600, WZ). Grant (2013) 163 from the Key Laboratory of Malignant Tumor Molecular Mechanism and

References

Andreyev, H. J. (2007). Gastrointestinal problems after pelvic radiotherapy: the past, the present and the future. *Clin. Oncol. R. Coll. Radiologists (Great Britain)* 19 (10), 790–799. doi:10.1016/j.clon.2007.08.011

Barr, W., and Naismith, W. C. (1972). Oral prostaglandins in the induction of labour. Br. Med. J. 2 (5807), 188–191. doi:10.1136/bmj.2.5807.188

Baughan, C. A., Canney, P. A., Buchanan, R. B., and Pickering, R. M. (1993). A randomized trial to assess the efficacy of 5-aminosalicylic acid for the prevention of radiation enteritis. *Clin. Oncol. R. Coll. Radiologists (Great Britain)* 5 (1), 19–24. doi:10. 1016/s0936-6555(05)80689-2

Cai, Z., Wang, S., and Li, J. (2021). Treatment of inflammatory bowel disease: a comprehensive review. *Front. Med.* 8, 765474. doi:10.3389/fmed.2021.765474

Cavicchioni, G., Fraulini, A., Falzarano, S., and Spisani, S. (2006). Structure-activity relationship of for-L-Met L-Leu-L-Phe-OMe analogues in human neutrophils. *Bioorg. Chem.* 34 (5), 298–318. doi:10.1016/j.bioorg.2006.07.001

Cooke, E. M. (1969). Faecal flora of patients with ulcerative colitis during treatment with salicylazosulphapyridine. *Gut* 10 (7), 565–568. doi:10.1136/gut.10.7.565

Hawkey, C. J., Boughton-Smith, N. K., and Whittle, B. J. (1985). Modulation of human colonic arachidonic acid metabolism by sulfasalazine. *Dig. Dis. Sci.* 30 (12), 1161–1165. doi:10.1007/BF01314051

Higgins, J. P. T. A. D., and Sterne, J. A. C. (2011). Chapter 8: assessing risk of bias in including studies. in Cochrane handbook for systematic reviews of interventions version 5.1. 0 (updated March 2011). Editor J. P. T. Higgins (The Cochrane Collaboration). Available online at: www.cochrane-handbook.org (Accessed August 8, 2014).

Hubenak, J. R., Zhang, Q., Branch, C. D., and Kronowitz, S. J. (2014). Mechanisms of injury to normal tissue after radiotherapy: a review. *Plastic Reconstr. Surg.* 133 (1), 49e–56e. doi:10.1097/01.prs.0000440818.23647.0b

Kiliç, D., Egehan, I., Ozenirler, S., and Dursun, A. (2000). Double-blinded, randomized, placebo-controlled study to evaluate the effectiveness of sulphasalazine in preventing acute gastrointestinal complications due to radiotherapy. *Radiotherapy Oncol. J. Eur. Soc. Ther. Radiology Oncol.* 57 (2), 125–129. doi:10.1016/s0167-8140(00) 00254-1

Kruis, W., Brandes, J. W., Schreiber, S., Theuer, D., Krakamp, B., Schütz, E., et al. (1998). Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative

Translational Medicine of Guangzhou Bureau of Science and Information Technology, and grant no. KLB09001 from the Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes also supported the present study.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that no Generative AI was used in the creation of this manuscript.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

colitis. Alimentary Pharmacol. and Ther. 12 (8), 707–715. doi:10.1046/j.1365-2036.1998. 00360.x

Loge, L., Florescu, C., Alves, A., and Menahem, B. (2020). Radiation enteritis: diagnostic and therapeutic issues. *J. Visc. Surg.* 157 (6), 475–485. doi:10.1016/j. jviscsurg.2020.08.012

Martenson, J. A., Jr., Hyland, G., Moertel, C. G., Mailliard, J. A., O'Fallon, J. R., Collins, R. T., et al. (1996). Olsalazine is contraindicated during pelvic radiation therapy: results of a double-blind, randomized clinical trial. *Int. J. Radiat. Oncol. Biol. Phys.* 35 (2), 299–303. doi:10.1016/0360-3016(96)00016-8

Mennie, A. T., Dalley, V. M., Dinneen, L. C., and Collier, H. O. (1975). Treatment of radiation-induced gastrointestinal distress with acetylsalicylate. *Lancet London, Engl.* 2 (7942), 942–943. doi:10.1016/s0140-6736(75)90358-x

Miller, R. C., Petereit, D. G., Sloan, J. A., Liu, H., Martenson, J. A., Bearden, J. D., 3rd, et al. (2016). N08C9 (alliance): a phase 3 randomized study of sulfasalazine versus placebo in the prevention of acute diarrhea in patients receiving pelvic radiation therapy. *Int. J. Radiat. Oncol. Biol. Phys.* 95 (4), 1168–1174. doi:10.1016/j.ijrobp. 2016.01.063

Najafi, M., Motevaseli, E., Shirazi, A., Geraily, G., Rezaeyan, A., Norouzi, F., et al. (2018). Mechanisms of inflammatory responses to radiation and normal tissues toxicity: clinical implications. *Int. J. Radiat. Biol.* 94 (4), 335–356. doi:10.1080/09553002.2018. 1440092

Nielsen, S. T., Beninati, L., and Buonato, C. B. (1988). Sulfasalazine and 5aminosalicylic acid inhibit contractile leukotriene formation. *Scand. J. Gastroenterol.* 23 (3), 272–276. doi:10.3109/00365528809093864

P, B. A., Sudha, S. P., Mohan, P., Patil, N., Rahman, A., Gundapuneedi, B. S., et al. (2024). Racecadotril versus loperamide in acute radiation enteritis: a randomized, double-masked, phase 3, noninferiority trial. *Int. J. Radiat. Oncol. Biol. Phys.* 118 (3), 616–625. doi:10.1016/j.ijrobp.2023.09.021

Pal, S., Adhikary, S., Bhattacharya, B., Basu, J., Ghosh, T., and Journal, NPJCCI (2013). A prospective randomized controlled trial to study the role of sulfasalazine in prevention of acute gastrointestinal toxicity associated with concurrent chemoradiation in carcinoma cervix. *Clin. Cancer Investig. J.* 2 (2), 118–121. doi:10.4103/2278-0513.113633

Rauch, K., and Weiland, H. (1972). Therapy of radiogenic colitis with salicylazosulfapyridine (azulfidine). *Strahlentherapie* 143 (6), 660-663.

Resbeut, M., Marteau, P., Cowen, D., Richaud, P., Bourdin, S., Dubois, J. B., et al. (1997). A randomized double blind placebo controlled multicenter study of mesalazine for the prevention of acute radiation enteritis. *Radiotherapy Oncol. J. Eur. Soc. Ther. Radiology Oncol.* 44 (1), 59–63. doi:10.1016/s0167-8140(97)00064-9

Sanguineti, G., Franzone, P., Marcenaro, M., Foppiano, F., and Vitale, V. (2003). Sucralfate versus mesalazine versus hydrocortisone in the prevention of acute radiation proctitis during conformal radiotherapy for prostate carcinoma. A randomized study. *Strahlenther. Onkol. Organ Dtsch. Rontgengesellschaft al* 179 (7), 464–470. doi:10.1007/ s00066-003-1082-4

Sann, H., Erichsen, J., Hessmann, M., Pahl, A., and Hoffmeyer, A. (2013). Efficacy of drugs used in the treatment of IBD and combinations thereof in acute DSS-induced colitis in mice. *Life Sci.* 92 (12), 708–718. doi:10.1016/j.lfs.2013.01.028

Sasaki, F., and Yokomizo, T. (2019). The leukotriene receptors as therapeutic targets of inflammatory diseases. *Int. Immunol.* 31 (9), 607–615. doi:10.1093/intimm/dxz044

Scheurlen, C., Allgayer, H., Kruis, W., Erdmann, E., and Sauerbruch, T. (1993). Effect of olsalazine and mesalazine on human ileal and colonic (Na+ + K+)-ATPase. *A possible diarrhogenic factor? Clin. investigator* 71 (4), 286–289. doi:10.1007/BF00184728

Singh, R. K., Gupta, S., Dastidar, S., and Ray, A. (2010). Cysteinyl leukotrienes and their receptors: molecular and functional characteristics. *Pharmacology* 85 (6), 336–349. doi:10.1159/000312669

Stenson, W. F., Mehta, J., and Spilberg, I. (1984). Sulfasalazine inhibition of binding of N-formyl-methionyl-leucyl-phenylalanine (FMLP) to its receptor on human neutrophils. *Biochem. Pharmacol.* 33 (3), 407–412. doi:10.1016/0006-2952(84)90233-8

Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA a cancer J. Clin.* 71 (3), 209–249. doi:10. 3322/caac.21660

Vilaseca, J., Salas, A., Guarner, F., Rodriguez, R., and Malagelada, J. R. (1990). Participation of thromboxane and other eicosanoid synthesis in the course of experimental inflammatory colitis. *Gastroenterology* 98 (2), 269–277. doi:10.1016/ 0016-5085(90)90814-h

Zimmerer, T., Böcker, U., Wenz, F., and Singer, M. V. (2008). Medical prevention and treatment of acute and chronic radiation induced enteritis--is there any proven therapy? a short review. *Z. fur Gastroenterol.* 46 (5), 441–448. doi:10.1055/s-2008-1027150